FT. LAUDERDALE, FL--(Marketwire - August 20, 2008) - OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated EDC solutions for clinical trials, today announced that the company is providing EDC software and services for a Phase II trial in BRCA 1/2 and HNPCC patients sponsored by the Tucson Arizona based biotech, Systems Medicine LLC (SML). SML initially began its relationship with OmniComm through OmniComm’s CRO Preferred Program™ and then selected OmniComm as its EDC vendor of choice for their Phase II study.
